Zobrazeno 1 - 10
of 554
pro vyhledávání: '"K A, Margolin"'
Publikováno v:
ESMO Open. 7:100598
Brain metastases are common in advanced melanoma and cause death in50% of patients. Until recently, median survival was only ∼4 months. Improved systemic treatment including immune checkpoint inhibitors and combinations of BRAF/MEK inhibitors, howe
Autor:
Thomas J. Smith, Nicholas J. Robert, David Cella, M L Citron, I C Henderson, Kishan J. Pandya, M Grove-Conrad, Martin D. Abeloff, John H. Fetting, Diane L. Fairclough, C K Osborne, Richard Gray, K A Margolin
Publikováno v:
Journal of Clinical Oncology. 16:2382-2391
PURPOSE The Intergroup conducted this breast cancer adjuvant trial to compare an investigational 16-week regimen with cyclophosphamide, doxorubicin, and fluorouracil (5-FU; CAF). The 16-week regimen features greater doxorubicin and 5-FU dose-intensit
Autor:
Murn, Lindsay T.1 lindsay.murn@mnsu.edu, Schultz, Laura C.2
Publikováno v:
Journal of College Student Mental Health. Jul-Sep2024, Vol. 38 Issue 3, p391-414. 24p.
Autor:
K A, Margolin
Publikováno v:
Seminars in oncology. 27(2)
Interleukin-2 (IL-2) administered in pharmacologic doses to renal cancer patients with intact organ function and good performance status induces durable complete responses in about 5% of patients and partial responses in an additional 10% to 15%. The
Autor:
J A, Sosman, F R, Aronson, M, Sznol, M B, Atkins, J P, Dutcher, G R, Weiss, R E, Isaacs, K A, Margolin, R I, Fisher, M L, Ernest, J, Mier, L, Oleksowicz, J R, Eckhardt, D, Levitt, J H, Doroshow
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 3(1)
Interleukin 6 (IL-6) has antitumor activity comparable to IL-2 in murine models with less toxicity. Because the biological effects of intermittent and continuous infusions may differ, we conducted two concurrent Phase I trials of daily x5, 1-h, and c
Autor:
G, Somlo, J H, Doroshow, S J, Forman, L A, Leong, K A, Margolin, R J, Morgan, J W, Raschko, S A, Akman, C, Ahn, I, Sniecinski
Publikováno v:
Cancer. 73(1)
This study was designed to establish the feasibility of combining high-dose cisplatin, etoposide, and cyclophosphamide followed by stem cell rescue in patients with responsive metastatic or high-risk primary breast cancer.Eligibility criteria include
Publikováno v:
Cancer. 71(7)
In an attempt to improve the complete remission and cure rate of advanced, bulky, high-risk germ cell cancer in men, a "high-dose" cisplatin, vinblastine, bleomycin, and etoposide (PVeBV) regimen was introduced.Ten men with biopsy-proven germ cell tu
Autor:
E M, Newman, S A, Akman, J S, Harrison, L A, Leong, K A, Margolin, R J, Morgan, J W, Raschko, G, Somlo, C W, Ahn, J H, Doroshow
Publikováno v:
Cancer research. 52(9)
Twenty-seven patients with advanced cancer were entered in a phase I study of bolus i.v. 5-fluorouracil at a dose of 370 mg/m2/day for 5 days combined with a continuous i.v. infusion of (6S)-folinic acid for 5.5 days, starting 24 h in advance of the
Autor:
Frederick R. Aronson, M H Bar, K A Margolin, M Sznol, J H Doroshow, M B Atkins, E R Gaynor, David H. Boldt, Geoffrey R. Weiss, J. P. Dutcher
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 10(2)
PURPOSE Since 1985, multiple centers have demonstrated that interleukin-2 (IL-2) and lymphokine-activated killer (LAK) cells produce durable anticancer responses in patients with metastatic renal cell carcinoma. High-dose recombinant IL-2 (rIL-2) has
Autor:
M, Sznol, J W, Mier, J, Sparano, E R, Gaynor, G R, Weiss, K A, Margolin, M H, Bar, M J, Hawkins, M B, Atkins, J P, Dutcher
Publikováno v:
Journal of biological response modifiers. 9(6)
Our group and others have conducted phase II trials of high-dose interleukin-2 (IL-2) or IL-2 with the adoptive transfer of in vitro activated lymphocytes in patients with advanced malignancies. Although durable complete and partial responses were se